8 results on '"Cardiac ischemic disease"'
Search Results
2. Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration
- Author
-
Andrea Caccioppo, Luca Franchin, Alberto Grosso, Filippo Angelini, Fabrizio D’Ascenzo, and Maria Felice Brizzi
- Subjects
cardiac ischemic disease ,cardiac regeneration ,stem cells ,exosomes ,therapeutic approaches ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Ischemic diseases in an aging population pose a heavy social encumbrance. Moreover, current therapeutic approaches, which aimed to prevent or minimize ischemia-induced damage, are associated with relevant costs for healthcare systems. Early reperfusion by primary percutaneous coronary intervention (PPCI) has undoubtedly improved patient’s outcomes; however, the prevention of long-term complications is still an unmet need. To face these hurdles and improve patient’s outcomes, novel pharmacological and interventional approaches, alone or in combination, reducing myocardium oxygen consumption or supplying blood flow via collateral vessels have been proposed. A number of clinical trials are ongoing to validate their efficacy on patient’s outcomes. Alternative options, including stem cell-based therapies, have been evaluated to improve cardiac regeneration and prevent scar formation. However, due to the lack of long-term engraftment, more recently, great attention has been devoted to their paracrine mediators, including exosomes (Exo) and microvesicles (MV). Indeed, Exo and MV are both currently considered to be one of the most promising therapeutic strategies in regenerative medicine. As a matter of fact, MV and Exo that are released from stem cells of different origin have been evaluated for their healing properties in ischemia reperfusion (I/R) settings. Therefore, this review will first summarize mechanisms of cardiac damage and protection after I/R damage to track the paths through which more appropriate interventional and/or molecular-based targeted therapies should be addressed. Moreover, it will provide insights on novel non-invasive/invasive interventional strategies and on Exo-based therapies as a challenge for improving patient’s long-term complications. Finally, approaches for improving Exo healing properties, and topics still unsolved to move towards Exo clinical application will be discussed.
- Published
- 2019
- Full Text
- View/download PDF
3. АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ И РЕМОДЕЛИРОВАНИЕ МИОКАРДА: СОВРЕМЕННЫЕ ВЗГЛЯДЫ, ВАРИАНТЫ, ОСОБЕННОСТИ
- Author
-
Тащук, B.
- Subjects
артериальная гипертензия ,ишемическая болезнь сердца ,ремоделирование миокарда ,артеріальна гіпертензія ,ішемічна хвороба серця ,ремоделювання міокарда ,arterial hypertension ,cardiac ischemic disease ,myocardial remodeling - Abstract
Modern concepts pertaining to the mechanisms of the onset of arterial hypertension, ischemic disease of the heart and remodeling of the myocardium are presented. Diagnostic methods, evaluation criteria and perspective trends in thestudy of this problem have been ascertained., Приведены современные представления о механизмах возникновения артериальной гипертензии, ишемической болезни сердца и ремоделирования миокарда. Освещены методы диагностики, критерии оценки и перспективные нап-равления в исследовании данной проблеммы., Наведені сучасні уявлення про механізми виникнення артеріальної гіпертензії, ішемічної хвороби серця та ремоделювання міокарда. Висвітлені методи діагностики, критерії оцінки та перспективні напрямки у вирішенні даної проблеми.
- Published
- 2022
4. Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration
- Author
-
Fabrizio D'Ascenzo, Luca Franchin, Andrea Caccioppo, Alberto Grosso, Maria Felice Brizzi, and Filippo Angelini
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Ischemia ,Review ,exosomes ,therapeutic approaches ,030204 cardiovascular system & hematology ,Regenerative medicine ,Catalysis ,lcsh:Chemistry ,Inorganic Chemistry ,03 medical and health sciences ,Extracellular Vesicles ,0302 clinical medicine ,stem cells ,Cell-Derived Microparticles ,Coronary Circulation ,medicine ,Humans ,Physical and Theoretical Chemistry ,Intensive care medicine ,lcsh:QH301-705.5 ,Molecular Biology ,Spectroscopy ,Clinical Trials as Topic ,business.industry ,Regeneration (biology) ,Organic Chemistry ,cardiac regeneration ,Percutaneous coronary intervention ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Microvesicles ,Computer Science Applications ,Clinical trial ,Oxygen ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Reperfusion Injury ,cardiac ischemic disease ,Stem cell ,business ,Reperfusion injury ,Stem Cell Transplantation - Abstract
Ischemic diseases in an aging population pose a heavy social encumbrance. Moreover, current therapeutic approaches, which aimed to prevent or minimize ischemia-induced damage, are associated with relevant costs for healthcare systems. Early reperfusion by primary percutaneous coronary intervention (PPCI) has undoubtedly improved patient’s outcomes; however, the prevention of long-term complications is still an unmet need. To face these hurdles and improve patient’s outcomes, novel pharmacological and interventional approaches, alone or in combination, reducing myocardium oxygen consumption or supplying blood flow via collateral vessels have been proposed. A number of clinical trials are ongoing to validate their efficacy on patient’s outcomes. Alternative options, including stem cell-based therapies, have been evaluated to improve cardiac regeneration and prevent scar formation. However, due to the lack of long-term engraftment, more recently, great attention has been devoted to their paracrine mediators, including exosomes (Exo) and microvesicles (MV). Indeed, Exo and MV are both currently considered to be one of the most promising therapeutic strategies in regenerative medicine. As a matter of fact, MV and Exo that are released from stem cells of different origin have been evaluated for their healing properties in ischemia reperfusion (I/R) settings. Therefore, this review will first summarize mechanisms of cardiac damage and protection after I/R damage to track the paths through which more appropriate interventional and/or molecular-based targeted therapies should be addressed. Moreover, it will provide insights on novel non-invasive/invasive interventional strategies and on Exo-based therapies as a challenge for improving patient’s long-term complications. Finally, approaches for improving Exo healing properties, and topics still unsolved to move towards Exo clinical application will be discussed.
- Published
- 2019
5. Enfermedad arterial coronaria o cardiopatía isquémica: dos entidades distinitas con diferentes procedimientos diagnósticos.
- Author
-
Vallejo, Enrique
- Subjects
- *
DIAGNOSIS , *CORONARY disease , *ISCHEMIA diagnosis , *ANGIOGRAPHY , *SINGLE-photon emission computed tomography , *TOMOGRAPHY , *PERFUSION - Abstract
Coronary artery disease (CAD) remains the leading cause of death in the Western world, and early detection of CAD allows optimal therapeutic management. The gold standard has always been invasive coronary angiography, but over the years various non-invasive techniques have been developed to detect CAD, including cardiac SPECT and cardiac computed tomography (Cardiac CT). Cardiac SPECT permitted visualization of myocardial perfusion and have focused on the assessment of the hemodynamic consequences of obstructive coronary lesions as a marker of CAD. Cardiac CT focuses on the detection of atherosclerosis rather than ischemia, and permit detection of CAD at an earlier stage. Objectives of this manuscript are to discuss the clinical experience with both modalities and to provide a critical review of the strengths and limitations of Cardiac SPECT and Cardiac CT for the diagnostic and management of patients with suspected CAD or cardiac ischemic disease. [ABSTRACT FROM AUTHOR]
- Published
- 2009
6. Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration.
- Author
-
Caccioppo, Andrea, Franchin, Luca, Grosso, Alberto, Angelini, Filippo, D'Ascenzo, Fabrizio, and Brizzi, Maria Felice
- Subjects
- *
COLLATERAL circulation , *REPERFUSION injury , *PERFUSION , *CARDIAC regeneration , *PERCUTANEOUS coronary intervention , *ISCHEMIA , *BLOOD flow - Abstract
Ischemic diseases in an aging population pose a heavy social encumbrance. Moreover, current therapeutic approaches, which aimed to prevent or minimize ischemia-induced damage, are associated with relevant costs for healthcare systems. Early reperfusion by primary percutaneous coronary intervention (PPCI) has undoubtedly improved patient's outcomes; however, the prevention of long-term complications is still an unmet need. To face these hurdles and improve patient's outcomes, novel pharmacological and interventional approaches, alone or in combination, reducing myocardium oxygen consumption or supplying blood flow via collateral vessels have been proposed. A number of clinical trials are ongoing to validate their efficacy on patient's outcomes. Alternative options, including stem cell-based therapies, have been evaluated to improve cardiac regeneration and prevent scar formation. However, due to the lack of long-term engraftment, more recently, great attention has been devoted to their paracrine mediators, including exosomes (Exo) and microvesicles (MV). Indeed, Exo and MV are both currently considered to be one of the most promising therapeutic strategies in regenerative medicine. As a matter of fact, MV and Exo that are released from stem cells of different origin have been evaluated for their healing properties in ischemia reperfusion (I/R) settings. Therefore, this review will first summarize mechanisms of cardiac damage and protection after I/R damage to track the paths through which more appropriate interventional and/or molecular-based targeted therapies should be addressed. Moreover, it will provide insights on novel non-invasive/invasive interventional strategies and on Exo-based therapies as a challenge for improving patient's long-term complications. Finally, approaches for improving Exo healing properties, and topics still unsolved to move towards Exo clinical application will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control
- Author
-
Domenico Scrutinio, Gabriella Ricci, Michele Gesualdo, Francesca Cortese, Marco Matteo Ciccone, Graziano Riccioni, Annapaola Zito, Massimo Iacoviello, Pasquale Caldarola, Annagrazia Cecere, Pietro Scicchitano, Rocco Lagioia, Santa Carbonara, and Michele Moncelli
- Subjects
medicine.medical_specialty ,Population ,Diastole ,Pharmaceutical Science ,Rhythm control ,Coronary Artery Disease ,Review ,Coronary artery disease ,Heart Rate ,Internal medicine ,Drug Discovery ,Heart rate ,medicine ,Animals ,Humans ,Ivabradine ,funny current ,education ,heart-rate lowering drugs ,Pharmacology ,Heart Failure ,education.field_of_study ,business.industry ,lcsh:RM1-950 ,Benzazepines ,medicine.disease ,chronic heart failure ,lcsh:Therapeutics. Pharmacology ,heart rate reduction ,Heart failure ,Cardiology ,cardiac ischemic disease ,Artery diseases ,business ,Cardiac ischemic disease ,Chronic heart failure ,Funny current ,Heart rate reduction ,Heart-rate lowering drugs ,medicine.drug - Abstract
Pietro Scicchitano,1 Francesca Cortese,1 Gabriella Ricci,1 Santa Carbonara,1 Michele Moncelli,1 Massimo Iacoviello,1 Annagrazia Cecere,1 Michele Gesualdo,1 Annapaola Zito,1 Pasquale Caldarola,2 Domenico Scrutinio,3 Rocco Lagioia,3 Graziano Riccioni,4 Marco Matteo Ciccone1 1Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, University of Bari, School of Medicine, Policlinico, Bari, Italy; 2Section of Cardiovascular Diseases, Policlinic, San Paolo Hospital, Bari, Italy; 3Section of Cardiovascular Diseases, Fondazione Maugeri, Cassano Murge, Italy; 4Intensive Cardiology Care Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, Italy Abstract: Elevated heart rate could negatively influence cardiovascular risk in the general population. It can induce and promote the atherosclerotic process by means of several mechanisms involving endothelial shear stress and biochemical activities. Furthermore, elevated heart rate can directly increase heart ischemic conditions because of its skill in unbalancing demand/supply of oxygen and decreasing the diastolic period. Thus, many pharmacological treatments have been proposed in order to reduce heart rate and ameliorate the cardiovascular risk profile of individuals, especially those suffering from coronary artery diseases (CAD) and chronic heart failure (CHF). Ivabradine is the first pure heart rate reductive drug approved and currently used in humans, created in order to selectively reduce sinus node function and to overcome the many side effects of similar pharmacological tools (ie, β-blockers or calcium channel antagonists). The aim of our review is to evaluate the role and the safety of this molecule on CAD and CHF therapeutic strategies. Keywords: chronic heart failure, heart rate reduction, cardiac ischemic disease, heart-rate lowering drugs, funny current
- Published
- 2014
8. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.
- Author
-
Scicchitano P, Cortese F, Ricci G, Carbonara S, Moncelli M, Iacoviello M, Cecere A, Gesualdo M, Zito A, Caldarola P, Scrutinio D, Lagioia R, Riccioni G, and Ciccone MM
- Subjects
- Animals, Benzazepines chemistry, Benzazepines pharmacology, Heart Rate drug effects, Humans, Ivabradine, Benzazepines therapeutic use, Coronary Artery Disease drug therapy, Heart Failure drug therapy
- Abstract
Elevated heart rate could negatively influence cardiovascular risk in the general population. It can induce and promote the atherosclerotic process by means of several mechanisms involving endothelial shear stress and biochemical activities. Furthermore, elevated heart rate can directly increase heart ischemic conditions because of its skill in unbalancing demand/supply of oxygen and decreasing the diastolic period. Thus, many pharmacological treatments have been proposed in order to reduce heart rate and ameliorate the cardiovascular risk profile of individuals, especially those suffering from coronary artery diseases (CAD) and chronic heart failure (CHF). Ivabradine is the first pure heart rate reductive drug approved and currently used in humans, created in order to selectively reduce sinus node function and to overcome the many side effects of similar pharmacological tools (ie, β-blockers or calcium channel antagonists). The aim of our review is to evaluate the role and the safety of this molecule on CAD and CHF therapeutic strategies.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.